Teva's asthma therapy chases GSK biologic with Phase III success
This article was originally published in Scrip
Teva Pharmaceutical Industries will seek approval for its asthma biologic Cinquil (reslizumab) in the US, EU and other markets in the first half of 2015 based on positive results from two Phase III clinical trials, putting the therapy about six months behind GlaxoSmithKline's competing monoclonal antibody Bosatria (mepolizumab).
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.